News

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

In an interview with HCPLive, Daniel Greer, PharmD discussed his team’s study on how antipsychotic injections were linked to a greater reduction in 30-day rehospitalizations than oral medication.

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

Vision screening rates for amblyopia showed substantial increase after photoscreening expansion, but patients who were Asian, Black, and Hispanic were less likely to be screened.

As diabetic retinopathy severity progresses, both vision-related and health-related scales show a significant deterioration in quality of life scores.

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Our January 2024 psychiatry month in review includes studies finding associations with depression, anxiety, and anorexia nervosa, as well as a phase 3 study looking into long-term safety of olanzapine, samidorphan.

January’s Dermatology Month in Review features 2 major FDA decisions, positive results on a new assessment tool, an evaluation of climate change’s impact on eczema, and more.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

Faricimab showed sustained vision improvements and retinal drying up to 72 weeks for both branch and central RVO in the phase 3 BALATON and COMINO studies.

This new warning for consumers cautions against use of Rebright, South Moon, or FivFivGo eye drops as a result of potential eye infection risks.

A systematic review suggests practitioners using enhanced empathy improves patient satisfaction, but research is hindered by inadequate reporting and heterogeneity.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our January 2024 month-in-review features crucial research on social determinants of health, updates on the latest ophthalmic pipeline developments, and a look at how the local environment affects eye health.

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.

In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

This analysis of current testing patterns in the US suggests a need for future studies to explore the rationale used to determine such testing decisions.

In a survey, 1 in 6 cisgender men and women reported unmet mental health needs at their latest visit with a healthcare professional. Mental health needs for other gender identities ranged from 1 in 5 and 1 in 4.

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Even when cholesterol levels were only moderately elevated, familial hypercholesterolemia variants were associated with greater cardiovascular risk.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

A recent analysis found risk factors linked to an embolism after VTE included Black race, interstitial fibrosis, advanced-stage disease, and increased operative duration.

In a study comparing readmission rates for patients with schizophrenia or schizoaffective disorder on oral or long-acting injections, investigators found after 30 days the readmission rate was 8.3% among patients who received pills and 1.9% among patients who received injections.

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

While this research did culminate in strong evidence regarding weight loss and its effects on lung airway responses, the precise mechanism for this phenomenon remains unknown.